A new clinical trial that will be run by Oxford/AstraZeneca will test the efficacy of the coronavirus vaccine on children as young as six years old.
Reports said the trial, which has at least 300 test subjects, began this weekend at the Oxford University and its partner sites in London, Southampton and Bristol.
The Oxford/AstraZeneca is one of three vaccines to have been approved for use in adults in the UK, along with Pfizer/BioNTech and Moderna.
Professor Andrew Pollard, chief investigator on the Oxford vaccine trial, said: “While most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination. These new trials will extend our understanding of control of SARS-CoV2 to younger age groups.”
Dr Grace Li, clinical research fellow from the Oxford Vaccine Group, said: “We’re going to give them doses either one month or three months apart, and we’re hoping to look to see which interval gives the best immune response.”
Dr Li said they were hoping to take five blood tests over 12 months to see how long the immune response lasts.
Under the trial, 240 children will receive the vaccine and the others will get a control meningitis jab.